Reducing Chronic Inflammation in Atherosclerosis with an Old Drug

Inflammation plays a crucial role in atherosclerosis progression. Recently, the COLCOT study has shown the benefits of colchicine in cardiovascular events. 

Colchicina para reducir la inflamación crónica de la aterosclerosis

This good old drug has an inflammatory effect which attenuates the NLRP3 cascade. This explains its effect on uric acid crystals in gout, which might be the same on atherosclerosis cholesterol crystals. 

This study called LoDoCo2 and published in Circulation, studied the potential anti-inflammatory effect of colchicine in patients with chronic coronary artery disease comparing lab exams 30 days before and after receiving the drug. 

It included 174 patients that had suffered acute coronary syndrome within the prior 6 months. 

A blood sample was obtained from all patients to quantify 184 proteins associated with inflammation at baseline, and another one after 30 days of receiving colchicine 0.5 mg/day plus all the standard medical treatment. 


Read also: AHA 2019 | COLCOT: Colchicine and the Return of the Anti-Inflammatory Theory.


At 30 days, there was a significant reduction of 37 proteins associated to inflammation (p<0.05). Attenuation of the NLRP3 inflammatory cascade was supported by a reduction of interleukin 18, IL-1 receptor antagonist, and IL-6. 

Other pro-inflammatory proteins not directly associated with the NLRP3 pathway also saw a reduction, especially those related to neutrophil degranulation. 

Conclusion

This study showed a significant reduction of multiple proteins related with inflammation after 30 days of treatment with low doses of colchicine in patients with chronic CAD. The anti-inflammatory effect of this drug exceeds the NLRP3 cascade effect, which suggests an important role in neutrophil inhibition. 

Original Title: Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease: A LoDoCo2 Proteomic Substudy.

Reference: Tjerk S.J. Opstal et al. Circulation. 2020 Nov 17;142(20):1996-1998. doi: 10.1161/CIRCULATIONAHA.120.050560.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ROUTE TRAIL: DKCRUSH vs. DKRUSH Culotte in Non-Left Main Bifurcation Lesions

Coronary bifurcation lesions represent a frequent technical challenge, making between 15% and 20% of cases. Though provisional stenting is mostly used, complex bifurcations are...

TENDERA: Comparing Conventional vs. Distal Transradial Occlusion for Coronary Interventions

Supported by robust data, favorably compared against the transfemoral, the transradial approach has consolidated as the safest method for percutaneous intervention, particularly in terms...

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ROUTE TRAIL: DKCRUSH vs. DKRUSH Culotte in Non-Left Main Bifurcation Lesions

Coronary bifurcation lesions represent a frequent technical challenge, making between 15% and 20% of cases. Though provisional stenting is mostly used, complex bifurcations are...

TENDERA: Comparing Conventional vs. Distal Transradial Occlusion for Coronary Interventions

Supported by robust data, favorably compared against the transfemoral, the transradial approach has consolidated as the safest method for percutaneous intervention, particularly in terms...

Asymptomatic Aortic Stenosis: A Complex Decision

Asymptomatic severe aortic stenosis continues to pose a significant challenge when it comes to clinical decision-making, often due to the difficulty in identifying symptoms....